Number of shares and votes in Calliditas Therapeutics
On April 29, 2022, Calliditas Therapeutics AB announced the allotment of 830,586 common shares under its 2018 warrant program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On April 29, 2022, Calliditas Therapeutics AB announced the allotment of 830,586 common shares under its 2018 warrant program. This increase brings the total number of shares and votes to 53,172,170. The company focuses on developing treatments for orphan diseases, with products like TARPEYO approved by the FDA and ongoing trials for setanaxib targeting primary biliary cholangitis and head and neck cancer. Calliditas shares are listed on Nasdaq Stockholm under the ticker CALTX and on Nasdaq Global Select Market as CALT.
Positive
- Allotment of 830,586 common shares boosts total shares to 53,172,170.
Negative
- None.
Details
News Market Reaction – CALT
The recorded move for CALT in the trading session of this news was -3.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOCKHOLM, April 29, 2022 /PRNewswire/ -- During April, Calliditas Therapeutics AB (publ) has allotted 830,586 common shares within the company's warrant program issued in 2018. Thus, as of April 29, 2022, the number of shares and votes in the company amounts to 53,172,170.
For further information, please contact:
Mikael Widell, Investor relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 a.m. CEST on April 29, 2022.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, TARPEYOTM (budesonide) delayed release capsules, has been approved by the FDA and is the subject of a marketing authorization application (MAA) with the European Medicines Agency (EMA). Additionally, Calliditas is conducting a pivotal clinical trial with its NOX inhibitor product candidate setanaxib in primary biliary cholangitis and is initiating a head and neck cancer Phase 2 trial with setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Number of shares and votes April 2022 |
View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301536113.html
SOURCE Calliditas Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.